ArticleMultiple sclerosis (Houndmills, Basingstoke, England)2022

Serum contactin-1 as a biomarker of long-term disease progression in natalizumab-treated multiple sclerosis.

Zoë Ygj van Lierop et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.